ENANTA PHARMACEUTICALS, INC Current Federal Tax Expense (Benefit)
ENANTA PHARMACEUTICALS, INC (ENTA) reported Current Federal Tax Expense (Benefit) of -$1.77 million for the 12-month period ending 2025-09-30, per its 10-K filed 2025-11-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2025-11-19
- ENANTA PHARMACEUTICALS, INC current federal tax expense (benefit) for the quarter ending 2019-09-30 was $2.18M.
- ENANTA PHARMACEUTICALS, INC current federal tax expense (benefit) for the quarter ending 2019-06-30 was $186.00K.
- ENANTA PHARMACEUTICALS, INC current federal tax expense (benefit) for fiscal 2025 was -$1.77M.
- ENANTA PHARMACEUTICALS, INC current federal tax expense (benefit) for fiscal 2024 was -$1.94M, a 176.76% decline from fiscal 2023.
- ENANTA PHARMACEUTICALS, INC current federal tax expense (benefit) for fiscal 2023 was $2.52M.
- ENANTA PHARMACEUTICALS, INC current federal tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Current Federal Tax Expense (Benefit) 3 month | Current Federal Tax Expense (Benefit) 6 month | Current Federal Tax Expense (Benefit) 9 month | Current Federal Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2025-09-30 | -$1.77M 10-K · filed 2025-11-19 | |||
| 2024-09-30 | -$1.94M 10-K · filed 2025-11-19 | |||
| 2023-09-30 | $2.52M 10-K · filed 2025-11-19 | |||
| 2022-09-30 | $0.00 10-K · filed 2024-11-27 | |||
| 2021-09-30 | -$28.72M 10-K · filed 2023-11-22 | |||
| 2020-09-30 | -$8.49M 10-K · filed 2022-11-23 | |||
| 2019-09-30 | $2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-24 | $2.37M derived: sum of 2 quarters · filed 2021-11-24 | $1.84M 10-K · filed 2021-11-24 | |
| 2019-06-30 | $186.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-10 | -$340.00K 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | -$526.00K 10-Q · filed 2020-05-11 | |||
| 2018-09-30 | $16.45M 10-K · filed 2020-11-25 | |||
| 2017-09-30 | $10.08M 10-K · filed 2019-11-27 | |||
| 2016-09-30 | $12.23M 10-K · filed 2018-11-29 | |||
| 2015-09-30 | $35.04M 10-K · filed 2017-12-11 | |||
| 2014-09-30 | $0.00 10-K · filed 2014-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |